Redbud NA1 transfer to manufacturing

Active Grant Awarded

Award ID
SB1AI191998
Recipient
Awarding agency
Obligated
$956,224

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 11% complete
Place of performance
Durham, NC 27709, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, awarded Redbud Labs, Inc. a grant with $956,224 obligated on July 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds transfer of REDBUD NA1, an ultra-compact nucleic acid sample prep platform for disease surveillance, into manufacturing. The work runs under a Commercialization Readiness Pilot tied to an ongoing SBIR contract and targets product quality, cost, and production capacity. Deliverables are framed around making the platform suitable for qPCR and sequencing workflows in high-containment and field-forward settings, where current manual and large-automation extraction methods fall short. The period of performance ends June 30, 2029. Place of performance is Durham, NC 27709. The program supports biomedical research and research training in infectious diseases and related areas, and this award's source describes no sub-recipients.

Description

Abstract
Predicting and containing epidemic disease requires ubiquitous surveillance of people, livestock, and wildlife for emerging strains of disease. The two most powerful tools for this surveillance are qpcr and sequencing, both of which require high-quality nucleic acids (NA) purified from a wide range of biological, environmental, and industrial samples. NA extraction is a major barrier for research groups; today, IT is either performed manually or with large automation equipment, and neither provides the reliable, robust, convenient solution required for these demanding environments. Typically, surveillance applications operate at medium throughput, using translational assays, and often in resource-limited settings such as high-containment or field-forward environments. As part of an ongoing sbir contract, we have developed redbud NA1, an ultra-compact sample prep platform ideally suited to disease surveillance applications. In this commercialization readiness pilot (CRP), we seek funding to transfer redbud NA1 into manufacturing. Our project address issues of product quality, cost, and production capacity.

Quick answers

Who received award SB1AI191998?

SB1AI191998 was awarded to Redbud Labs, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 22, 2026.

How much is award SB1AI191998 worth?

$956,224 has been obligated on SB1AI191998.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award